Skip to main
BDTX
BDTX logo

BDTX Stock Forecast & Price Target

BDTX Analyst Ratings

Based on 9 analyst ratings
Strong Buy
Strong Buy 56%
Buy 44%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Black Diamond Therapeutics Inc. is making strides in oncology with its pipeline drug BDTX-1535, which demonstrated a 36% Overall Response Rate (ORR) in a targeted subset of non-small cell lung cancer (NSCLC) patients, showing potential for improvement to 42% after refining the patient population. The company’s unique approach to targeting non-classical EGFR mutations addresses an unmet need, providing a competitive edge as current therapies fail to adequately treat these cases. With 74% of patients remaining on treatment after an initial follow-up of 4.7 months, the encouraging initial results, combined with expected data updates from ongoing studies in 2025, suggest a viable regulatory path and growth potential for the company's stock.

Bears say

Black Diamond Therapeutics Inc faces several significant risks that contribute to a negative outlook, including potential negative efficacy data for its drug BDTX-1535 and the possibility of poor safety profiles or adverse clinical data for its pipeline candidates. The company has also adjusted its expense assumptions and commercialization timeline, resulting in a downward revision of its target price, reflecting concerns about its financial trajectory. Additionally, for the full year 2025, Black Diamond is projected to incur a net loss of $1.32 per share, further emphasizing ongoing financial instability and risk of dilution for investors.

BDTX has been analyzed by 9 analysts, with a consensus rating of Strong Buy. 56% of analysts recommend a Strong Buy, 44% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Black Diamond Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Black Diamond Therapeutics (BDTX) Forecast

Analysts have given BDTX a Strong Buy based on their latest research and market trends.

According to 9 analysts, BDTX has a Strong Buy consensus rating as of Jun 16, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $30.56, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $30.56, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Black Diamond Therapeutics (BDTX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.